SOURCE-LINKED STUDY SUMMARY
Tirzepatide 10 mg and 15 mg versus semaglutide 7.2 mg: an indirect treatment comparison
Sponsor announcement summarizedQuality not appraised
- What was studied
- An adjusted indirect comparison used SURMOUNT-1 and STEP UP data to compare weight loss.
- Who / model studied
- Adults with obesity. The analyzed sample size was not verified from the full poster.
- Studied dose & schedule
- Tirzepatide 10 or 15 mg versus injectable semaglutide 7.2 mg; outcomes compared at 72 weeks.
- What the study found
- Treatment-regimen estimates favored tirzepatide by 3.2 and 4.5 percentage points at 10 and 15 mg. Efficacy-estimand advantages were smaller, 0.7 and 1.8 points, and statistically uncertain. Adverse-event discontinuation rates were comparable.
- Limitations & context
- Sponsor-reported indirect comparison, not randomization between these treatments. Results depend on the estimand, how treatment discontinuation is handled. Residual cross-trial differences may remain. Full poster not reviewed; comparable discontinuation does not establish equivalent overall safety.
Read summary source ↗ · Prepared 9/29/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: sponsor announcement, full poster not reviewed. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.